α-Synuclein Pathology and Therapeutic Modulation

α-Synuclein is a presynaptic protein that, under physiological conditions, plays roles in synaptic vesicle trafficking and neurotransmitter release. In neurodegenerative disorders collectively termed synucleinopathies, misfolded α-synuclein assembles into soluble oligomers and insoluble fibrils that deposit as Lewy bodies, triggering synaptic dysfunction, mitochondrial impairment and neuronal death. Pathological spread occurs via a prion-like mechanism in which extracellular aggregates seed intracellular aggregation. Therapeutic strategies have thus focused on inhibiting aggregation at multiple stages, enhancing clearance of misfolded species, modulating cellular stress pathways and blocking intercellular transmission. Small molecules and peptides may stabilise native conformations or redirect misfolded forms into non-toxic assemblies. Immunotherapies aim to neutralise extracellular aggregates and promote microglial clearance. Meanwhile, approaches to boost autophagy and lysosomal degradation seek to restore proteostatic balance. Advances in high-throughput screening, structural biology of the intrinsically disordered ensemble and in vivo imaging are accelerating the identification of lead compounds. Translational challenges include achieving selectivity for pathogenic species without perturbing physiological α-synuclein function, ensuring blood–brain barrier penetration and demonstrating long-term disease modification in clinical cohorts.

Research from Nature Portfolio

In silico and molecular dynamics studies have identified derivatives of 7,8-dihydroxyflavone as promising inhibitors of α-synuclein aggregation. Carbamic ester modifications enhance binding affinity to aggregation-prone regions of the protein and demonstrate favourable drug-likeness and ADMET profiles in computational assays. Simulations reveal stable intermolecular interactions under dynamic conditions, suggesting these compounds may prevent the formation of toxic oligomers and fibrils. These findings propose a rational framework for lead optimisation and provide molecular insights into targeting intrinsically disordered regions of α-synuclein.

α-Synuclein Pathology and Therapeutic Modulation publication trend

The graph below shows the total number of articles in α-synuclein pathology and therapeutic modulation across all publications each year (not limited to Nature Index journals).

Technical terms

α-Synuclein: An intrinsically disordered presynaptic protein implicated in synaptic vesicle regulation and at the centre of protein aggregation in synucleinopathies.

Oligomer: A small assembly of misfolded α-synuclein monomers; these soluble species are often more neurotoxic than mature fibrils.

Fibrillation: The process by which α-synuclein monomers and oligomers convert into insoluble, β-sheet-rich fibrils, forming the core of Lewy bodies.

Lewy body: A cytoplasmic inclusion composed predominantly of α-synuclein fibrils, characteristic of Parkinson’s disease and related disorders.

Autophagy: A cellular degradation pathway whereby cytoplasmic components, including misfolded proteins, are sequestered in autophagosomes and delivered to lysosomes for clearance.

References

1. Targeting Alpha-Synuclein as a Therapy for Parkinson’s Disease. Frontiers in Molecular Neuroscience (2019).
2. Design and Molecular dynamic Investigations of 7,8-Dihydroxyflavone Derivatives as Potential Neuroprotective Agents Against Alpha-synuclein. Scientific Reports (2020).
3. Targeting the Intrinsically Disordered Structural Ensemble of α-Synuclein by Small Molecules as a Potential Therapeutic Strategy for Parkinson’s Disease. PLOS ONE (2014).
4. High-Throughput Screening Methodology to Identify Alpha-Synuclein Aggregation Inhibitors. International Journal of Molecular Sciences (2017).
5. Alpha-Synuclein Aggregation Pathway in Parkinson’s Disease: Current Status and Novel Therapeutic Approaches. Cells (2022).
6. Protein aggregation-inhibition: a therapeutic route from Parkinson’s disease to sickle cell anemia. Critical Reviews in Biochemistry and Molecular Biology (2023).